Ecromeximab Explained

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1]

The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[2]

References

  1. http://www.ama-assn.org/ama/upload/mm/365/ecromeximab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab
  2. http://adisinsight.springer.com/drugs/800013219 Adis insight: Ecromeximab

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ecromeximab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.